Long-term oral carvedilol in chronic heart failure.

about

Sympathoinhibitory effect of statins in chronic heart failure.Electroacupuncture improves cardiac function and remodeling by inhibition of sympathoexcitation in chronic heart failure rats.High dose ascorbic acid does not reverse central sympathetic overactivity in chronic heart failure.

P2860

Q33807131-5F5F994A-E349-4913-A621-F25E381C92B6 Q47904948-3B4CD71B-AC4F-4327-86EF-B1DA8A583603 Q48900191-63939D83-5E2E-451E-B4ED-513277873218

P2860

Long-term oral carvedilol in chronic heart failure.

Item

http://www.wikidata.org/entity/Q44910691

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh

2004年學術文章

@zh-hant

name

Long-term oral carvedilol in chronic heart failure.

@en

Long-term oral carvedilol in chronic heart failure.

@nl

type

Item

label

Long-term oral carvedilol in chronic heart failure.

@en

Long-term oral carvedilol in chronic heart failure.

@nl

prefLabel

Long-term oral carvedilol in chronic heart failure.

@en

Long-term oral carvedilol in chronic heart failure.

@nl

P1476

Long-term oral carvedilol in chronic heart failure.

@en

P2093

Andrea Di Lenarda

http://www.w3.org/2001/XMLSchema#string

Gastone Sabbadini

http://www.w3.org/2001/XMLSchema#string

Gianfranco Sinagra

http://www.w3.org/2001/XMLSchema#string

Michele Moretti

http://www.w3.org/2001/XMLSchema#string

P2860

Carvedilol prevents epinephrine-induced apoptosis in human coronary artery endothelial cells: modulation of Fas/Fas ligand and caspase-3 pathway

Clinical Pharmacology of Carvedilol.

Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial.

Beta-blockade in heart failure: selective versus nonselective agents.

Do beta-blockers prolong survival in heart failure only by inhibiting the beta1-receptor? A perspective on the results of the COMET trial.

Selective versus nonselective beta-blockade for heart failure therapy: are there lessons to be learned from the COMET trial?

A clinical pharmacologist's response to Dr Milton Packer's perspective on the results of the COMET trial.

Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study.

Carvedilol inhibits endothelin-1 biosynthesis in cultured human coronary artery endothelial cells.

Radical-scavenging and iron-chelating properties of carvedilol, an antihypertensive drug with antioxidative activity.

P304

1359-1372

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14656566.5.6.1359

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2004-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15163280

http://www.w3.org/2001/XMLSchema#string

Long-term oral carvedilol in chronic heart failure.

about

P2860

P2860

Long-term oral carvedilol in chronic heart failure.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698